255 related articles for article (PubMed ID: 37240077)
21. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.
Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL
Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733
[TBL] [Abstract][Full Text] [Related]
22. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
[TBL] [Abstract][Full Text] [Related]
23. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
[TBL] [Abstract][Full Text] [Related]
24.
Abba MC; Canzoneri R; Gurruchaga A; Lee J; Tatineni P; Kil H; Lacunza E; Aldaz CM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049922
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
26. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
Woodard GA; Price ER
AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
[TBL] [Abstract][Full Text] [Related]
27. Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer.
Rivenbark AG; Coleman WB
Exp Mol Pathol; 2012 Dec; 93(3):391-8. PubMed ID: 23142414
[TBL] [Abstract][Full Text] [Related]
28. LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
Deshpande RP; Sharma S; Liu Y; Pandey PR; Pei X; Wu K; Wu SY; Tyagi A; Zhao D; Mo YY; Watabe K
Breast Cancer Res; 2022 Jan; 24(1):6. PubMed ID: 35078502
[TBL] [Abstract][Full Text] [Related]
29. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Khurana A; McKean H; Kim H; Kim SH; mcguire J; Roberts LR; Goetz MP; Shridhar V
Breast Cancer Res; 2012 Mar; 14(2):R43. PubMed ID: 22410125
[TBL] [Abstract][Full Text] [Related]
30. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
31. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
32. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
33. Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features of Ductal Carcinoma In Situ.
Tokura M; Nakayama J; Prieto-Vila M; Shiino S; Yoshida M; Yamamoto T; Watanabe N; Takayama S; Suzuki Y; Okamoto K; Ochiya T; Kohno T; Yatabe Y; Suto A; Yamamoto Y
Cancer Res; 2022 Sep; 82(18):3236-3248. PubMed ID: 35852797
[TBL] [Abstract][Full Text] [Related]
34. Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA.
Ahmadpour ST; Orre C; Bertevello PS; Mirebeau-Prunier D; Dumas JF; Desquiret-Dumas V
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958880
[TBL] [Abstract][Full Text] [Related]
35. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
[TBL] [Abstract][Full Text] [Related]
36. Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2019 May; 189(5):966-974. PubMed ID: 30273605
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
38. Genome evolution in ductal carcinoma in situ: invasion of the clones.
Casasent AK; Edgerton M; Navin NE
J Pathol; 2017 Jan; 241(2):208-218. PubMed ID: 27861897
[TBL] [Abstract][Full Text] [Related]
39. Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
[TBL] [Abstract][Full Text] [Related]
40. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
